REGN Faces Mixed Outlook as Q4 Earnings Approach

REGN Faces Mixed Outlook as Q4 Earnings Approach. With anticipated EPS showing a slight decline, investor sentiment may be cautious leading up to the earnings report. Despite a bullish consensus rating, the company's recent struggles with sales might influence stock performance.

Date: 17-01-2025

AI Rating: 5

Earnings Per Share (EPS) The report indicates that analysts expect Regeneron Pharmaceuticals to post a profit of $9.57 per share for Q4, reflecting a decrease from $10.18 per share in the same quarter last year. This decline may lead to cautious investor sentiment. Looking ahead, EPS for fiscal 2024 is projected to be $37.72, showing a marginal increase from $37.66 in fiscal 2023. The EPS forecast for fiscal 2025 indicates a further growth of 2.3% year-over-year, reaching $38.57. Revenue Growth The report highlights that Regeneron reported better-than-expected Q3 adjusted EPS of $12.46 and revenue of $3.7 billion. However, this positive aspect is somewhat overshadowed by a significant 21% decline in sales for Eylea, the company's key product, which missed estimates and raised concerns among investors. Market performance appears shaky, with REGN shares declining 25.1% over the past 52 weeks compared to a 25.1% rise in the S&P 500 Index. Stakeholders are also worried about regulatory setbacks, such as the FDA’s complete response letter for linvoseltamab, which further weighs on the outlook. Overall, despite the positive EPS projections and bullish consensus from analysts, the concerns surrounding product sales and market performance could influence investor decisions and stock prices significantly.

Stocks: REGN